Paediatric Rheumatology
Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis
S.T. Leinonen1, K. Aalto2, K.M. Kotaniemi3, T.T. Kivelä4
- Department of Ophthalmology, University of Helsinki, Helsinki University Hospital, Finland. sanna.leinonen@hus.fi
- Department of Paediatrics, University of Helsinki, Helsinki University Hospital, Finland.
- Department of Ophthalmology, University of Helsinki, Helsinki University Hospital, Finland.
- Department of Ophthalmology, University of Helsinki, Helsinki University Hospital, Finland.
CER9793
2017 Vol.35, N°6
PI 1043, PF 1046
Paediatric Rheumatology
Free to view
(click on article PDF icon to read the article)
PMID: 29148422 [PubMed]
Received: 28/07/2016
Accepted : 14/12/2016
In Press: 14/11/2017
Published: 12/12/2017
Abstract
OBJECTIVES:
To evaluate the association of adalimumab trough levels and anti-adalimumab antibodies with activity of uveitis in juvenile idiopathic arthritis-related uveitis.
METHODS:
This was a retrospective observational case series in a clinical setting at the Department of Ophthalmology, Helsinki University Hospital, Finland in 2014-2016. Thirty-one paediatric patients with chronic anterior juvenile idiopathic arthritis-related uveitis in 58 eyes and who had been on adalimumab ≥6 months were eligible for the study. Uveitis activity during adalimumab treatment, adalimumab trough levels and anti-adalimumab antibody levels were recorded.
RESULTS:
Anti-adalimumab antibody levels ≥12 AU /ml were detected in nine patients (29%). This level of anti-adalimumab antibodies was associated with a higher grade of uveitis (p<0.001), uveitis that was not in remission (p=0.001) and with lack of concomitant methotrexate therapy (p=0.043). In patients with anti-adalimumab antibody levels <12 AU/ml, higher serum trough levels did not associate with better control of uveitis (p=0.86).
CONCLUSIONS:
Adalimumab treatment might be better guided by monitoring anti-adalimumab antibody formation in treating JIA-related uveitis.
